AT, the positive control, was able to lower serum pro-inflammatory cytokine production, reduce serum cholesterol, hepatic free cholesterol, serum alpha-fetoprotein (AFP) and ALT levels, and ameliorate NASH (Domech et al., 2021; Zhang X, et al., 2021). This evidence concerns the gene AFP and metabolic dysfunction-associated steatohepatitis.